Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases

US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat various progressive fibrosing lung diseases, excluding idiopathi …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news